Metastases have been widely thought to arise from rare, selected, mutation-bearing cells in the primary tumor. Recently, however, it has been proposed that breast tumors are imprinted ab initio with metastatic ability. Thus, there is a debate over whether 'phenotypic' disease progression is really associated with 'molecular' progression. We profiled 26 matched primary breast tumors and lymph node metastases and identified 270 probesets that could discriminate between the two categories. We then used an independent cohort of breast tumors (81 samples) and unmatched distant metastases (32 samples) to validate and refine this list down to a 126-probeset list. A representative subset of these genes was subjected to analysis by in situ hybridization, on a third independent cohort (57 primary breast tumors and matched lymph node metastases). This not only confirmed the expression profile data, but also allowed us to establish the cellular origin of the signals. One-third of the analysed representative genes (4 of 11) were expressed by the epithelial component. The four epithelial genes alone were able to discriminate primary breast tumors from their metastases. Finally, engineered alterations in the expression of two of the epithelial genes (SERPINB5 and LTF) modified cell motility in vitro, in accordance with a possible causal role in metastasis. Our results show that breast cancer metastases are molecularly distinct from their primary tumors.
Introduction
Metastases are the leading cause of death in cancer patients. A widely accepted conjecture (the 'most advanced clone' theory) holds that metastatic cells are the result of rare genetic events arising late during tumor progression (Fidler and Kripke, 1977) . These events lead to the acquisition of an invasive phenotype, thus conferring an advantage to the altered clone. The advent of post-genomic technologies has allowed direct testing of this hypothesis in human cancers. This has led to the proposal that the metastatic phenotype may be an intrinsic property of the primary tumor (the 'ab initio' theory), as supported by gene expression profile analyses of early-stage breast cancers that identified an expression signature predictive of metastasis (van de Vijver et al., 2002; van't Veer et al., 2002; Ramaswamy et al., 2003; Wang et al., 2005) .
A possibly unifying scenario derives from two sets of observations. First, it has been reported that while the breast cancer cell line MDA-MB-231 possesses the poorprognosis signature, sub-populations of these cells, forming highly aggressive metastases in different organs, are characterized by additional independent organ-specific expression fingerprints (Kang et al., 2003; Minn et al., 2005b) . In this contention, a lung-specific metastasis signature has been reported to be biologically meaningful and clinically relevant (Minn et al., 2005a (Minn et al., , 2007 Gupta et al., 2007) . Moreover, it was found that in breast cancer tumor cells might disseminate at an early stage of progression, but still might acquire genetic aberrations typical of the metastatic state thereafter (Schmidt-Kittler et al., 2003; Gangnus et al., 2004) . Thus, while tumors-at least in the case of breast tumors-might be imprinted ab initio with metastatic ability, the actual acquisition of the phenotype might depend on additional genetic changes (Kang et al., 2003; Schmidt-Kittler et al., 2003; Gangnus et al., 2004; Yang et al., 2004; Minn et al., 2005a Minn et al., , b, 2007 Gupta et al., 2007) .
One important prediction of this 'unifying scenario' is that metastases should be genetically different, to some extent, from their primary tumors, which might be reflected in differences in their gene expression profiles. To date, there is no clear evidence in this direction, and data in favor of, or against, the molecular diversity of breast primary tumors and their metastases have been reported (Weigelt et al., 2003 (Weigelt et al., , 2005 Hao et al., 2004; Feng et al., 2007; Suzuki and Tarin, 2007) . Again, this is not surprising given the paramount impact of individual genetic noise in this type of analysis, the limited number of samples analysed (and, sometimes, their heterogeneity) , and the difficulty of determining the impact of noncancerous or non-metastatic tissue contamination from the host organs. Notwithstanding, continued efforts aimed at resolving this issue are warranted, first and foremost from the therapeutic viewpoint, if the development of metastasis-specific targeting strategies is to remain a viable option. In the present study, we tackled this problem with the intent of verifying whether, in breast cancer, primary tumors are distinct, at the expression profile level, from their metastases.
Results

Study design
The general strategy of our approach is illustrated in Figure 1 . We profiled 26 matched breast tumors and lymph node metastases ('cohort 1', Figure 1a) . Samples, selected for this study, showed high tumor cellularity in both the primary and metastatic lesions (70-90%, see also Supplementary Figure 1 for representative examples, and Supplementary Table 1 for clinical and pathological information). We identified 270 probesets that can discriminate between primary tumors and paired metastases (Figure 1b) . Then, we validated this list on an independent group of 81 breast tumors and 32 unrelated distant metastases ('cohort 2', Figure 1c , Supplementary Table 1 ). This second level of refinement allowed us to reduce the list to 126 probesets ( Figure 1c ).
We employed in situ hybridization (ISH) on tumor tissue microarrays (TMAs) to establish the cellular origin of the signals of a representative group of genes, from the 126-probeset list (Figure 1e ). This was performed both on a subset of samples from cohort 1, and on a third independent cohort ('cohort 3') of breast tumors and matched lymph node metastases (Figure 1f ). This led to the identification of four epithelial genes (Figure 1g ), which could, independently from other genes, separate primary tumors from metastases in cohorts 1 and 2.
Finally, we performed an initial biological characterization of representative bona fide metastasis-specific epithelial genes (Figure 1h ).
Identification of a set of genes that differentiates between primary breast tumors and their lymph node metastases We initially analysed the expression profiles of 26 matched primary tumors and synchronous axillary lymph node metastases (cohort 1), using Affymetrix oligo-array technology. As previously reported (Perou et al., 2000; Weigelt et al., 2003 Weigelt et al., , 2005 Feng et al., 2007) , unsupervised hierarchical clustering showed that primary tumors tended to group with their affiliated metastases (21 out of 26 cases, Supplementary Figure 2a ). To identify a metastasis-specific set of genes, three different statistical approaches were undertaken (see Materials and methods and Figure 1a) . Irrespective of the method used, gene expression differences could be readily detected, which allowed the separation of primary tumors from lymph node metastases with degrees of confidence of up to 85-90% (Supplementary Figures 2b and c) . Notably, the three approaches identified partially overlapping lists of genes ( Figure 1) . A group of 270 probesets, corresponding to 222 unique genes, was evidenced by at least two out of three approaches (Figure 1 , lists of all probesets are in Supplementary Identification of epithelial and stromal genes (Table 1) Identification of a 4-gene metastatic signature (Fig. 5A ) Figure 1 Study design. The overall strategy of the study is depicted. Details are in the main text and in Materials and methods. In (a), a Venn's diagram is shown, representing the overlap among the three-probeset lists generated by the three statistical methods applied.
Molecular progression in breast cancer M Vecchi et al expression were confirmed by real-time PCR analysis, which gave 82% concordance with the initial MAS5 Comparison Analysis (data not shown). The 270-probeset list could separate primary breast tumors from lymph node metastases with 85% accuracy (Figure 2a) .
To validate the 270-probeset list, we employed a second cohort of samples (cohort 2) composed of 32 distant breast tumor metastases of breast cancers, profiled by us for the purpose of the present study, and 81 lymph node-positive primary breast cancers, selected among those profiled by Ivshina et al. (2006) on the basis of the presence of lymph node metastases . The 270-probeset list was able to separate primary breast tumors from distant metastases, in cohort 2, with 85% accuracy (Figure 2b ). The availability of the independent set of samples of cohort 2 allowed a further refinement of our list by statistical analysis. This led to the identification of a list of 126 probesets able to discriminate between primary breast tumors and distant metastases with 96% accuracy (Figure 2c ). This reduced gene list was still able to separate primary tumors from lymph node metastases in the initial dataset (cohort 1) with 80% accuracy (Figure 2d ). Obviously, these findings do not implicate that the molecular mechanisms of metastases to the lymph nodes and to distant organs are completely overlapping, but simply that a common signature, possibly indicative of partially overlapping mechanisms, can be identified.
In situ analysis by tissue microarrays To establish the cellular origin of the signals detected in the expression profile screening, we employed ISH on TMAs. A pool of 17 genes, derived from the 126-probeset list was selected, based on the percentages of differential regulation computed across the paired samples of cohort 1 by the MAS5 comparison analysis (Table 1) . In particular, genes were considered eligible for analysis when their major trend of regulation ranged between 46 and 77%, and when they displayed opposite Molecular progression in breast cancer M Vecchi et al regulation in less that one-third of all cases. Importantly, this pool of 17 genes retained the ability to discriminate between primary tumors and lymph node metastases (in cohort 1) with >90% accuracy (Supplementary Figure 3) ; the 17 genes are, therefore, representative of the 126-probeset list. We initially used the 17 genes to screen a subset of samples of cohort 1 (16 samples in total). Normal lymph nodes and normal breast tissues were also analysed as controls. Of the 17 analysed transcripts, 11 could be detected reliably. The remaining genes showed negative or barely detectable signals, likely due to low mRNA abundance ( Table 1 ). The ISH analysis allowed us to identify three categories of genes:
(i) genes expressed preponderantly by the epithelial component (four genes: SERPINB5, MMP7, APOD and LTF), (ii) genes expressed preponderantly by fibroblasts (three genes: SFRP2, POSTN and FN1) and (iii) genes expressed preponderantly by the 'immune' component of the lymph node (macrophages and lymphocytes) or by the vascular endothelium (four genes: MMP9, CXCR4, C7 and IGFBP3) ( Table 1) .
We would like to emphasize that our ISH analysis does not establish an absolute criterion of 'expression specificity' for the analysed genes, also given the relative low sensitivity of the methodology that might underestimate low levels of expression. Rather, ISH identifies the major cellular type that expresses a given gene. For practical purposes, however, this is most likely sufficient to establish whether differential expression between tumors and metastases, evidenced in the profiling experiments, can be attributed to the epithelial component or to stromal (fibroblast, immune or vascular) components of the analysed tissues. We then utilized a third independent cohort of 57 primary breast cancers and matched lymph node metastases (cohort 3) to further confirm the ISH data, and to provide a semi-quantitative in situ assessment of the relevance of the epithelial-and, as an additional control, the fibroblast-expressed genes ( Figure 3 , Table 2 , Supplementary Figure 4) . The immune and endothelial genes were considered to be 'contaminants', for the purpose of this study, and eliminated from further analysis (see also Discussion).
The ISH-TMA approach not only allowed us to verify the cellular origin (epithelial or stromal) of the signals but also confirmed that, in keeping with the expression profile data, all the analysed genes were consistently downregulated in lymph node metastases ( Figure 3 , Table 2 , Supplementary Figure 4) . Importantly, for both SERPINB5 and APOD, for which reliable antibodies were available, we were able to further confirm the ISH expression results at the protein level by immunohistochemistry ( Figure 4) . Importantly, the four epithelial genes alone could separate primary tumors from their matched lymph node metastases with B80% accuracy on cohort 1 samples (Figure 5a ), and with B70% accuracy on cohort 2 (not shown). Thus, the four epithelial genes constitute by themselves a metastatic signature.
LTF and SERPINB5 control epithelial cell migration
To investigate how the epithelial genes of the signature can potentially affect the metastatic phenotype, we measured . Note that HE staining is sufficient to establish the cellular origin of the signal, and in some cases superior to other methodologies, such as staining with a pan cytokeratin antibody (see Supplementary  Figure 1 for data). We also note that, in a small fraction of cases (10 and 24%, respectively), FN1 and POSTN were also expressed by epithelial cells, although the level of intensity of the signal was always below that of the surrounding stromal cells (data not shown).
The staining pattern of normal breast parenchyma, from the same patients is reported in Supplementary Figure 4 . Original magnification Â 100.
Molecular progression in breast cancer M Vecchi et al their ability to control epithelial cell migration. We selected the MDA-MB-231 cell line, recently used to establish the impact of certain gene signatures on metastatic potential in vivo (Kang et al., 2003; Minn et al., 2005a Minn et al., , b, 2007 Gupta et al., 2007) . Since, as expected, the parental MDA-MB-231, and its various subclones, displaying highly metastatic phenotypes (Kang et al., 2003; Minn et al., 2005a, b) do not express the four epithelial genes (not shown), we re-expressed SERPINB5, MMP7, APOD and LTF (alone or in combination) in the 4175 subclone of MDA-MB-231. As shown in Figure 5b , all four genes were efficiently expressed, while they were nearly undetectable in the control population. Real-time PCR analysis revealed that we achieved expression levels of the four genes that were comparable to those of normal mammary primary cells (Figure 5b) . Next, the various populations were subjected to a Boyden chamber migration assay. Either SERPINB5 or LTF, alone, significantly inhibited cell motility. The combined expression of these two genes or the simultaneous expression of all four genes did not further enhance this inhibition (Figure 5c ). Of note, only the migratory ability of cells was affected; other phenotypes, such as cell proliferation, were unchanged (Supplementary Figure 5 ). These observations suggest that, at least in part, our 'epithelial metastasis signature' may play a role in tumor dissemination. Molecular progression in breast cancer M Vecchi et al 2154 primary tumor). Our results, therefore, speak in favor of molecular progression of breast cancer metastases, with respect to the primary tumor. It is important, however, to stress that while differences at the expression profile might reflect genetic changes, they could also be due to other mechanisms. Thus, the final validation of the concept of genetic progression of breast cancer metastasis will need further investigation.
Epithelial genes vs non-epithelial genes One important question, addressed in our study, concerned the cellular origin of the signals detected in the expression profile experiments. This led to the identification of a signature constituted of four epithelial genes (epithelial genes are for practical purposes defined here as genes 'preponderantly' expressed by the epithelial component, see Results) that could separate both primary tumors from their lymph node metastases and primary tumors from distant metastases to several organs with B70-80% accuracy. We feel that additional comments are necessary with regard to the emphasis that we place on the identification of an epithelial signature. Of course, we do not mean to underestimate the impact, or the relevance, of stromal (expressed by fibroblasts, or endothelial cells, or immune cells) genes in metastasis. We simply caution about a possible caveat in our expression profiling experiments, that is, the fact that some of the differences, detected by us, in the expression of non-epithelial genes could be caused by 'artifacts', due to tissue heterogeneity, or to organ-specific factors (see below).
As a case in point, the immune genes present in our list were clearly expressed by lymphocytes and macrophages in the actual samples that were used for the gene profiling experiments. Thus, in all probability, they should be considered to be contaminants. We note that some of these genes, that is, CXCR4 and MMP9, have been implicated in the process of metastasis and even detected in breast epithelial cells (Muller et al., 2001; Hiratsuka et al., 2002; Rolli et al., 2003) . In addition, it is known that tumor-infiltrating immune cells can influence the natural history of a tumor (Dave et al., 2004) . Thus, our definition of 'contaminant' does not negate a possible biological role, but simply reflects the fact that the presence of these genes in our list is likely due to the presence of lymphoid tissue in our lymph node metastasis specimens.
The situation is more uncertain for the three fibroblastgenes. SFRP2, POSTN and FN1 were significantly downregulated in the peritumoral fibroblasts of nodal metastases compared with the peritumoral fibroblasts of their paired primary tumors, irrespective of the quantity of stroma present in each tissue specimen ( Figure 3 , Table 2 ). All three genes were not expressed by normal breast fibroblasts (POSTN was however expressed by the normal epithelium), indicating that their expression in the tumor sample must be due to their induction in the stromal compartment by the epithelial tumor component (Supplementary  Figure 4) . This observation is in line with other evidence that stromal components might play an important role in metastasis (Allinen et al., 2004; Kuperwasser et al., 2004; Schedin and Elias, 2004) . The loss of expression of SFRP2, POSTN and FN1 in metastases could be due to changes in the epithelial metastatic component (with consequent inability to induce the fibroblasts genes) and therefore might represent a read-out of metastasis-specific changes of the epithelial component. However, it could also simply reflect lack of responsiveness of the fibroblasts in the metastatic organ. In this latter case, while the presence of these genes in our list might still be relevant to the biology of metastasis, it would not be of immediate value for the addressing of the issue of molecular progression. It will, therefore, be important to address this issue in future studies.
Biological relevance of the epithelial-gene signature For the above reasons, we feel that it was important to confirm that a 'metastasis signature' could be identified also when considering epithelial genes alone. In our proof-of-principle approach, we identified four such genes (SERPINB5, MMP7, APOD and LTF). For these genes, there is solid literature indicating an association between their loss of expression and cancer, and unfavorable prognosis and/or metastatic ability of breast cancers. For example, SERPINB5 (also called MASPIN) has been implicated in determining the metastatic potential of breast cancer cell lines (Zou et al., 1994; Reddy et al., 2001; Shi et al., 2001; Beltran et al., 2007) and prostate cancer metastasis (Luo et al., 2007) . APOD expression by breast carcinomas is associated with a favorable outcome, and its expression is decreased in metastatic lymph nodes; APOD is also epigenetically silenced in esophageal squamous cell carcinomas (Lamelas et al., 2000; Yamashita et al., 2002) . LTF inhibits the growth of solid tumors and the development of experimental metastases in mice (Bezault et al., 1994; Ushida et al., 1998) . While a comprehensive review of the literature will be impossible here, it is clear that our signature identifies a set of genes, whose involvement in the progression of human tumors can already be strongly inferred.
An important question remains regarding the nature of the selective advantage of the loss of expression of the identified epithelial genes in the natural history of the tumor, if any. For SERPINB5 and LTF, we could show that their re-expression in a mammary metastatic cell line significantly reduced cell migration. Thus, one might speculate that loss of expression of SERPINB5 or LTF could induce an enhanced migratory phenotype. It remains to be established whether the in vitro phenotype that we highlighted is indeed translated into enhanced metastatic ability in vivo. Previous literature supports this possibility, as it has been shown that overexpression of SERPINB5/MASPIN in breast cancer cell lines, reduces their metastatic potential (Zou et al., 1994; Reddy et al., 2001; Shi et al., 2001) .
How many metastasis signatures?
A number of previous studies have tried to identify signatures that specifically distinguish primary breast Molecular progression in breast cancer M Vecchi et al cancers from their lymph node metastases. Some of these studies reported that no such signatures could be discovered (Weigelt et al., 2003 (Weigelt et al., , 2005 Hao et al., 2004) . However, two recent studies identified signatures of 79 (Feng et al., 2007) , and 155 genes (Suzuki and Tarin, 2007) , respectively, that could do so (other 'metastasis signatures', not directly identified in breast cancer are discussed in Supplementary Information). These two signatures share genes with our 126-probeset list: 21 out of 79 (Feng et al., 2007) and 26 out of 155 (Suzuki and Tarin, 2007) , respectively. Apparently, therefore, there is partial concurrence between our study and those of Feng et al. and Suzuki et al. However, we feel that conclusions in this direction are premature. In both the mentioned studies, the authors did not establish the cellular origin of the signals, and we did so, in our study, only for a representative subset of genes. Indeed, only one of our epithelial genes (MMP7) is present in the 79-gene (Feng et al., 2007) and 155-gene (Suzuki and Tarin, 2007) lists. Thus, additional studies are needed to establish whether the partial overlap between the lists really reflects the fact that our group, Feng et al., and Suzuki et al. have discovered the 'same' metastatic signature, or whether this is a consequence of the fact that common contaminants are frequent in this kind of approach.
How do our results fit in the context of the present debate on the origin of metastatic cells? Breast tumors are most likely imprinted with metastatic ability ab initio (van de Vijver et al., 2002; van't Veer et al., 2002; Ramaswamy et al., 2003) . Yet, recent molecular findings (reviewed in (Gupta and Massague, 2006) ) also indicate genetically driven selection. The two concepts are not mutually exclusive and 'integrated' scenarios have been put forward, which contemplate the existence of metastasis 'initiation', 'progression' and 'virulence' genes Minn et al., 2007; Nguyen and Massague, 2007) . Metastasis initiation genes are supposed to provide an advantage in the primary tumor and to allow 'enabling conditions' for metastases. Progression genes contribute to primary tumor development but also perform functions that are advantageous at the site of metastases. Genes of these two categories should be found in signatures detected in primary tumors. Conversely metastasis virulence genes are supposed to provide an advantage at the site(s) of metastasis, and not in the primary tumor, and should therefore not be present in signatures detected in primary tumors, but rather in signatures that distinguish metastases from their primary tumors (Nguyen and Massague, 2007) . Under this scenario, the metastasis signature described here seems to possess the characteristics of a metastasis virulence signature.
Materials and methods
Tissue samples, RNA extraction, GeneChip hybridization and QRT-PCR Tissue specimens of 'cohort 1' (paired primary breast tumors and lymph node metastases) were obtained in the same surgical act, before any therapy, from 26 women (age 27-75, mean 50, Supplementary Table 1 ). Written informed consent for research use of biological samples was obtained from all patients, and the research project was approved by the Institutional Ethical Committees. Samples were immediately snap-frozen in liquid nitrogen and stored at À80 1C. Part of the sample was formalin-fixed and embedded in paraffin blocks. The first and the last sections of each frozen sample were stained with haematoxylin and eosin, and analysed for cellularity. Samples, selected for this study, showed high tumor cellularity in both the primary and metastatic lesions (70-90%, see Supplementary Figure 1 for representative examples), and were processed as such without microdissection.
Total RNA was extracted from 10 to 20 serial sections (10 mm thick) of snap-frozen specimens using commercial homogenization (QIAshredder) and purification (RNeasy Mini Kit) reagents (Qiagen, Valencia, CA, USA). RNA was analysed with the Agilent 2100 Bioanalyzer (Agilent Technologies, Milan, Italy). Total RNA (500 ng) was amplified using the T7-Polymerase-based double linear amplification protocol (Eberwine et al., 1992) . cRNA probes (25 mg) were hybridized onto the Affymetrix (Santa Clara, CA, USA) HG-U133A ChipSet, according to Affymetrix technical protocols. The average intensity of each array was scaled to a predefined value (target intensity) of 500, in order to make arrays comparable.
QRT-PCR was performed as described in Supplementary Methods.
Statistical analysis
A detailed description of the data analysis performed on the datasets obtained from profiling the 26 breast tumors and their synchronous lymph node metastases (cohort 1) is provided in Supplementary Methods. Briefly, a first level of analysis was performed using the GeneChip Microarray Analysis Suite version 5.0 (MAS5) 'Comparison Analysis' algorithm, by directly comparing each tumor sample (baseline array) to its corresponding lymph node metastasis (experimental array). Expression profile data, pre-processed by MAS5, were exported to GeneSpring version 7.0 (Silicon Genetics, Redwood City, CA, USA). A one-way analysis of variance (Welch's approximate t-test), with multiple testing corrections according to the Benjamini and Hochberg False Discovery Rate procedure, was performed. Probesets with sufficiently small P-values (Po0.05) were returned. A third level of analysis was performed via Support Vector Machine with recursive feature elimination (RFE), trained by a proper M-Fold Cross Validation procedure, which was stratified and reinforced by many random subdivisions of data, and properly tailored to RFE algorithm.
The 270-probeset list obtained from the above analyses was further validated on an independent set of samples, comprising 81 primary breast tumors and 32 unrelated distant metastases (cohort 2). Datasets for the 81 primary tumors were from Ivshina et al. (2006) . In detail: original RAW data (CEL files) were downloaded from GEO (http://www.ncbi.nlm.nih.gov/ geo/, accession code GSE4922, (Ivshina et al., 2006) ). Of the 289 samples present in Ivshina et al. dataset, only those representing primary breast tumors with lymph node metastases (81 cases total) were selected for our analysis. The 32 distant metastases of cohort 2 were processed in-house. Statistical analysis was performed as described above, using the GeneSpring software, resulting in a list of 126 probesets with a corrected P-value o0.05.
Tissue microarray studies TMAs were prepared (Kononen et al., 1998) and analysed (Capra et al., 2006) as previously described. For each patient, two representative cores of the primitive cancer, two cores of the nodal metastasis and two cores of a negative lymph node were arrayed. Moreover, in each TMA used, at least 10 normal breast tissues were included as controls. To evaluate gene expression, two pathologists independently counted all tumor cells in each TMA core and up to 1000 cells in the whole section using a dark-field condenser for the silver grains. An initial semi-quantitative scale was established: 0 (no staining), 1 (1-25 grains per cell; weak staining), 2 (26-50 grains per cell, moderate staining), and 3 (>50 grains per cell, strong staining). The average scores between the two representative cores were then calculated, resulting in a final arbitrary scale: 0, 0.5, 1, 1.5, 2, 2.5, 3. A difference of at least 1.5, on the arbitrary scale, was used to establish over-or underexpression.
Immunostaining for SERPINB5 and APOD was performed using mouse monoclonal antibodies from Novocastra (Newcastle upon Tyne, UK) and Zymed, (San Francisco, CA, USA), respectively.
Cell migration assay
Full-length cDNAs for the genes of interest were obtained as described in Supplementary Methods, and cloned into the retroviral vector pBABE-puro. The 4175 subclone of MDA-MD-231 was infected with the appropriate retroviral constructs. Cells were serum-starved overnight and transferred onto transwells (5 mm pores, 24-well plates, Corning Incorporated Costar, Corning, NY, USA). Uncoated membranes were used for migration assays. Cells (3 Â 10 4 ), in 100 ml of assay medium, were seeded in the upper chamber, and 500 ml of complete medium was added to the lower chamber. Cells were incubated at 37 1C for 8 h, fixed and stained with 4', 6-diamidino-2-phenylindole. Cells that remained on the upper surface were mechanically removed with a cotton swab, and cells migrated on the lower surface were counted (4 fields at 10 Â magnification per transwell).
